Boston Scientific Corporation $BSX Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC lifted its stake in Boston Scientific Corporation (NYSE:BSX) by 140.9% during the first quarter, Holdings Channel reports. The institutional investor owned 931,155 shares of the medical equipment provider’s stock after acquiring an additional 544,637 shares during the quarter. SG Americas Securities LLC’s holdings in Boston Scientific were worth $58,430,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BSX. FWL Investment Management LLC purchased a new position in Boston Scientific during the second quarter valued at approximately $26,000. Swiss RE Ltd. purchased a new stake in Boston Scientific in the 4th quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific during the 4th quarter worth approximately $26,000. Colonial Trust Co SC increased its holdings in shares of Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 231 shares in the last quarter. Finally, Bangor Savings Bank increased its holdings in shares of Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 142 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently issued reports on BSX shares. Truist Financial lowered their price target on shares of Boston Scientific from $85.00 to $64.00 and set a “buy” rating on the stock in a report on Thursday, June 4th. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Piper Sandler reiterated an “overweight” rating and issued a $65.00 price objective on shares of Boston Scientific in a research report on Friday, June 12th. Wells Fargo & Company reissued an “equal weight” rating and set a $55.00 target price (down from $75.00) on shares of Boston Scientific in a research note on Thursday, May 28th. Finally, Leerink Partners dropped their target price on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating on the stock in a research report on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and an average price target of $85.08.

Boston Scientific Stock Down 2.2%

BSX stock opened at $44.30 on Tuesday. Boston Scientific Corporation has a 52 week low of $44.05 and a 52 week high of $109.50. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The firm has a 50-day simple moving average of $54.37 and a 200-day simple moving average of $72.44. The stock has a market capitalization of $65.84 billion, a P/E ratio of 18.53, a P/E/G ratio of 0.87 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same period last year, the company posted $0.75 EPS. Boston Scientific’s quarterly revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts forecast that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has approved a share buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling at Boston Scientific

In other news, Director Cheryl Pegus bought 1,770 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the transaction, the director directly owned 1,770 shares in the company, valued at $99,987.30. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Edward J. Ludwig purchased 3,580 shares of the stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the purchase, the director directly owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 9,800 shares of company stock valued at $554,012 over the last quarter. 0.34% of the stock is currently owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.